IMRNNasdaqPharmaceutical PreparationsFiscal year ends June 30
Immuron Ltd
Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Sep 24, 2026
$0.96−0.03 (-2.62%)
Close on Oct 19, 2026
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0.0%
0M of 323M shares
Institutional holders
6
2 new, 3 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IMRN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Citadel Advisors LLC | 43,123 | 0.01% | $45.71K | +29,319 | 0.00% |
| Hrt Financial LP | 20,584 | 0.01% | $21 | New | 0.00% |
| Rhumbline Advisers | 7,367 | 0.00% | $7.81K | – | 0.00% |
| Bnp Paribas Arbitrage, Snc | 5,200 | 0.00% | $5.51K | +600 | 0.00% |
| Morgan Stanley | 1,700 | 0.00% | $1.80K | −28,874 | 0.00% |
| UBS Group AG | 363 | 0.00% | $385 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 6 | 0M | 0.0% | 2 / 2 | 1 / 3 | 0M | 0M |
| Q1 2026 | 7 | 0M | 0.0% | 2 / 2 | 3 / 4 | 0M | 0M |
| Q4 2025 | 9 | 0M | 0.1% | 2 / 4 | 2 / 0 | 0M | 0M |
| Q3 2025 | 7 | 0M | 0.0% | 2 / 2 | 1 / 0 | 0M | 0M |
| Q2 2025 | 5 | 0M | 0.0% | 3 / 0 | 0 / 1 | 0M | 0M |
| Q1 2025 | 3 | 0M | 0.0% | 2 / 0 | 0 / 0 | 0M | 0M |
| Q4 2024 | 1 | 0M | 0.0% | 0 / 0 | 0 / 2 | 0M | 0M |
| Q3 2024 | 3 | 0M | 0.0% | 0 / 1 | 1 / 1 | 0M | 0M |
| Q2 2024 | 4 | 0M | 0.0% | 0 / 2 | 1 / 3 | 0M | 0M |
| Q1 2024 | 7 | 0M | 0.0% | 4 / 0 | 2 / 1 | 0M | 0M |
| Q4 2023 | 4 | 0M | 0.0% | 0 / 1 | 0 / 0 | 0M | 0M |
| Q3 2023 | 4 | 0M | 0.0% | 0 / 0 | 2 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Paul Gerard Brennan | Chairman of the Board, Director | – | – | May 4, 2026 |
| Flavio Palumbo | Chief Commercial Officer | 1,142,909 | 0.35% | May 14, 2026 |
| Steven George Lydeamore | Chief Executive Officer | 3,155,047 | 0.98% | Apr 29, 2026 |
| Aaron James Laurita | Chief Financial Officer | – | – | Apr 29, 2026 |
| Jerry Kanellos | Chief Scientific Officer | 333,000 | 0.10% | Apr 29, 2026 |
| Daniel Jude Pollock | Director | 743,230 | 0.23% | May 14, 2026 |
| Jeannette Anne Joughin | Director | – | – | Apr 29, 2026 |
| Ravi Savarirayan | Director | 877,840 | 0.27% | Apr 29, 2026 |